ReviewBiomedicines2026
The Interplay Between Bone Biology and Iron Metabolism: Molecular Mechanisms and Clinical Implications.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From cell to disease: Regulatory networks and mechanisms of super‑enhancers in aging (Review).Molecular medicine reports · 2026Review
- Multi-Omics-Guided Discovery ofMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The maintenance of bone homeostasis requires the coordinated activity of specialized cells (osteoblasts, osteoclasts and osteocytes), soluble factors and hormones with regulatory functions. Disruption of this tightly controlled balance contributes to several skeletal pathological conditions, among which osteoporosis is one of the most prevalent. Iron, an essential element for the basic cellular functions of both osteoblasts and osteoclasts, plays a pivotal role in preserving bone homeostasis and skeletal integrity. Both iron deficiency and iron overload impair bone remodeling through distinct but converging mechanisms. Iron deficiency compromises collagen synthesis, alters hypoxia-dependent signaling, and may affect vitamin D metabolism, collectively predisposing the individual to reduced bone mineral density and increased fracture risk. Conversely, excess iron enhances oxidative stress, promotes osteoclastogenesis, and suppresses osteoblast differentiation and function, thereby favoring bone loss, particularly in the aging population and postmenopausal individuals. Hepcidin, the master regulator of systemic iron availability, has emerged as a key modulator of bone turnover, whereas the bone-derived hormone fibroblast growth factor 23 (FGF23) links iron imbalance to phosphate homeostasis, vitamin D metabolism, and inflammation. Beyond metabolic bone diseases, dysregulated iron handling is increasingly recognized as a hallmark of osteosarcoma biology, influencing tumor growth, metabolic reprogramming, and an individual's susceptibility to ferroptosis. The emerging, albeit only preclinical, evidence of the roles of iron and ferroptosis in osteosarcoma is therefore also covered. This review summarizes the current understanding of the interactions between iron metabolism and bone biology and addresses how an imbalance in iron metabolism may lead to major skeletal disorders. Overall, iron homeostasis could represent a potential target for preventing and treating osteoporosis and for improving therapeutic strategies for osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.